Pfizer Inc (PFE): PFE/Astellas—Xtandi full_dataset_from

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	826
Posts	119569
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 5462

Saturday, 04/29/2023 2:57:40 PM

Saturday, April 29, 2023 2:57:40 PM

PFE/Astellas—Xtandi full_dataset_from_phase-3 EMBARK trial_presented_at_AUA:

https://www.pfizer.com/news/press-release/press-release-detail/xtandir-enzalutamide-plus-leuprolide-reduced-risk

Astellas Pharma…and Pfizer…announced today that XTANDI (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide (Hazard Ratio [HR]: 0.42; 95% Confidence Interval [CI], 0.30–0.61; P<0.0001), as assessed by the primary endpoint of metastasis-free survival (MFS), in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR).

These data from the Phase 3 EMBARK trial, which evaluated patients across three study arms (XTANDI plus leuprolide [n=355], placebo plus leuprolide [n=358], or XTANDI monotherapy [n=355]), were presented as a plenary session during the 2023 American Urological Association Annual Meeting…

Please see #msg-171466844 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”